Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864601 | 0.76 | MKNK1 (0.57) | MEN1RXFP1KMT2AMAPTBRS3 | |
| SCHEMBL5740980 | 0.76 | TRPV1 (0.51) | SMARCA4PBRM1TRPV1 | |
| SCHEMBL4866606 | 0.76 | TRPV1 (0.55) | MKNK1TRPV1 | |
| SCHEMBL14111444 | 0.73 | LIMK1 (0.49) | MEN1KMT2ARAB9ALMNAMAPT | |
| SCHEMBL17298892 | 0.72 | AR (0.57) | MEN1RXFP1KMT2AMKNK1TRPV1 | |
| SCHEMBL4985286 | 0.72 | KMT2A (0.43) | MEN1RXFP1KMT2ARAB9AHTT | |
| SCHEMBL1549990 | 0.72 | KMT2A (0.51) | MEN1KMT2ARAB9AHTTSMN1; SMN2 | |
| SCHEMBL4978504 | 0.72 | BRS3 (0.43) | MEN1KMT2ARAB9AHTTSMN1; SMN2 | |
| SCHEMBL4871319 | 0.72 | MKNK1 (0.55) | BRS3MKNK1TRPV1 | |
| SCHEMBL4868405 | 0.71 | TRPV1 (0.59) | MKNK1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713807-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070929-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| EP-1713807-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070929-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MEN1 3499/4885RXFP1 986/4885KMT2A 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.